Current status and next steps

Haileyesus Getahun
Coordinator
IACG Secretariat
World Health Organization
The Interagency Coordination Group on AMR (IACG) was established by the order of the 2016 political declaration on AMR.

United Nations

General Assembly

Seventy-first session
Agenda item 127

Resolution adopted by the General Assembly on 5 October 2016

[without reference to a Main Committee (A/71/L.2)]

71/3. Political declaration of the high-level meeting of the General Assembly on antimicrobial resistance
Mandate and Members of the IACG

- Providing practical guidance for approaches needed to ensure sustained effective global action to address AMR
- Recommendations including on options to improve coordination taking into account the global action plan
- Report to the UN Secretary-General in May 2019

Secretariat provided by WHO with contributions from FAO and OIE
Terms of reference of IACG

• Raise awareness and support implementation of major global priorities, tools and standards for reducing AMR, including the Global Action Plan on AMR and supporting the SDGs

• Coordinate mapping of actions being taken by UN agencies, other organizations and key stakeholders towards achieving measurable results, and identify opportunities for collaboration, as well as gaps, redundancies, and duplication

• Promote, plan and facilitate collaborative action to align activities so gaps are closed and resources are optimally distributed

• Explore the feasibility of developing global goals and ambitions related to AMR for UN agencies, component members, and, where appropriate, other stakeholders, for priorities set out in the declaration

• Regularly report on progress and on IACG meetings and to issue a full report to the UNGA at its 73rd session, through the Secretary-General, keeping Member States, stakeholders and the governing bodies of WHO, FAO and OIE fully apprised of progress
Progress to date

• Developed a workplan following web based consultation
• Organised its work in six areas

1. Communication and awareness
2. National action plans
3. Optimize use of antimicrobials
4. Innovation, R & D and access
5. Surveillance and monitoring
6. Governance and SDG alignment

• Conducted mapping of stakeholders and activities
• Raised the profile of AMR including in a Call to Action event
• Public consultation of discussion papers conducted
• Bracing for recommendations and report through inclusive process
• Seven meetings conducted and reports and documents prepared
Who are interested in IACG work?

- National action plans
- R & D and access
- Surveillance

Very few member states and CSOs from the “South” provided feedback.

- Communication and awareness
- Optimize use of antimicrobials
- Governance
IACG major milestones – September 2018 to May 2019

- **IACG finalize 1st set of recommendations**
  - 24-26 Oct

- **Subgroups finalize recommendations October 12**

- **IACG meeting to agree on first draft report**
  - 17-19 Dec

- **Call to Action**
  - Accra, Ghana
  - 19-20 Nov

- **IACG meeting to sign off final report**
  - End Mar

- **Drafting of recommendations**

- **Familiarization and anchoring process**

- **Online consultation on first draft**

- **Regional consultations**

- **1st draft report**

- **2nd draft (final) report**

- **Final report submitted to UNSG**
The question- too many recommendations already exist
Innovative for breakthrough actions
Disruptive for what is not working
Catalytic for existing recommendations
Process of recommendation drafting and progress of subgroups

June-August
- Discussion papers
- Consultation on discussion papers

September - December
- Problem statement
- Identify solutions
- Draft recommendations
- Draft report
- Consultation on draft report
- Final report

Communication and awareness
National Action Plans
Optimise use
R&D and Access
Governance
Surveillance and monitoring

IACG (International Antimicrobial Resistance Coordination Group)
Eight categories identified for IACG recommendation
(Cutting across human, animal, plant and environment health with high focus on impact and results at country level)

- **Accountability**: obligation and responsibilities of entities and stakeholders
- **Coordination**: actions for coordination among stakeholders and actors
- **Financing**: resource needs and investment at all levels and for all purposes including sources of funding and financing mechanisms
- **Governance**: options of improved coordination and actions for impact at all levels, areas and sectors as deemed relevant
- **Implementation**: catalyse implementation programmes and policies
- **Integration and mainstreaming**: integration and mainstreaming of AMR agenda at all levels and in all forms and sectors
- **Impact and result at country level**: to bring impact and result at country level with different aspects of the AMR response
- **Regulation and enforcement**: items on regulation related issues and their enforcement
Keep in touch with IACG secretariat

• Visit the website at http://www.who.int/antimicrobial-resistance/interagency-coordination-group/en/

• Follow @uniacgamr on twitter

• Send your queries, comments and suggestions at iacg-secretariat@who.int
Global framework for development and stewardship to combat antimicrobial resistance: state of play
1-2 October 2018, Geneva, Switzerland

Peter Beyer
Senior Advisor
Department of Essential Medicines and Health Products
WHO
Goal of consultation

• Present the possible goals, form, structure, content of a possible global AMR framework

• Stimulate discussion among stakeholder and Member States

• Receive feedback to further develop concept and content

• Discuss and define a process to chart a way forward
1st Informal Consultation of Member States and Partners
9-10 November 2017

- Convened by WHO with FAO and OIE
- Focused on the updated draft roadmap of the Framework and next steps

Member States called for the Tripartite to:
- Develop concrete elements of the framework through a stepwise approach
- Employ a One Health approach
Background

In the *Political Declaration of the High Level Meeting of the General Assembly on Antimicrobial Resistance*, world leaders called on WHO together with FAO and OIE to finalize the Global framework for development and stewardship to combat antimicrobial resistance.

The draft framework:

An umbrella text uniting different tools and instruments that is being developed through a stepwise approach over time.

Developed by WHO, FAO, OIE and in collaboration with UN Environment.
Covers the whole value chain (of products)
A strong international instrument(s) that drives change at the local, regional, national and global level addressing current gaps in the governance of AMR through defining appropriate goals, standards and targets.
10 goals of the Framework

1. Countries set individual long-term/realistic targets with a stepwise implementation plan and timeline to reduce the need and, consequently, the use of antimicrobials in the human, animal and plant sectors.

2. Increase access to and appropriate use of quality-assured first-line antibiotics for human health and limit the use of reserve/last-resort antibiotics by implementing antimicrobial stewardship programmes.

3. Increase access to and reduce shortages of essential and effective antibiotics by ensuring their continued availability.

4. Implement international codes and standards to promote worldwide responsible and prudent use of antimicrobials in animals (terrestrial and aquatic) and plants.

5. Phase out the use of antibiotics for animal growth promotion and plant protection in the absence of risk analysis.
6. Use of fluoroquinolones, third- and fourth-generation cephalosporins, and colistin should be guided by the following considerations:

- Do not use as preventive treatment applied by feed or water.
- Do not use as first-line treatment unless justified.
- Use as second-line treatment should ideally be based on bacteriological tests.
- Extra-label or off-label use should be reserved to instances where no alternatives are available.

7. Increase investment and capacity building in clean water, sanitation and hygiene (WASH), infection prevention and control (IPC), vaccination programmes, and good animal (terrestrial and aquatic) husbandry practices and biosecurity measures where needed to limit the emergence and spread of AMR.

8. Increase investment in developing new antibiotics, alternatives to antibiotics, diagnostics and vaccines for use in humans, animals and plants.

9. Increase investment, research and surveillance of antimicrobials and resistant microorganisms in the environment to better understand the role of the environment in the dynamics of AMR and the relevance of the contributions from anthropogenic sources.

10. Limit the release of active pharmaceutical ingredients into the environment, especially into water, and ensure environmentally sound management of obsolete stocks.
Chapter 2: Legal form

- WHO Pandemic Influenza Preparedness Framework
- FAO Global Plan of Action for Animal Genetic Resources
- OIE Standards on the Quality of Veterinary Services
- Codex Alimentarius Code of Practice to Contain and Minimize AMR
- WHO International Health Regulations (2005)

WHO Framework Convention on Tobacco Control
FAO International Plant Protection Convention
Convention on Biological Diversity
Considerations regarding legal form

- **Different options** with individual strengths and weaknesses ranging from non-binding (code of conduct) to binding (convention, WHO regulation)

- **Binding vs. non-binding not a binary question**: Recent international treaties that are binding, incorporate maximum flexibility (e.g. Paris Convention on Climate Change)

- **Governance** differs depending on instrument

- **Form and method of adoption** should reflect purpose and content of the framework

- Content needs to be further developed to allow identification of ideal form of the instrument(s)
Chapters 3-5
R&D, Access & Stewardship, Environment

Content of the chapters:

• Key challenges and objectives
• Basic principles
• Potential targets
• Responsibilities of the Tripartite and UN Environment

To be developed:

• Responsibilities of Member States and other stakeholders
Chapter 3. R&D to foster access

Basic principles:

- Invest in R&D for new antimicrobials, improvement and reformulation of existing antibiotics, alternatives to antimicrobials, diagnostic tools, vaccines for human, animal and plant health
- R&D should be needs-driven, evidence-based and guided by the principles of affordability, effectiveness and efficiency, equity and appropriate, and prudent use of antimicrobials that need to be considered from the outset
- The cost of investment in R&D on AMR should be de-linked from the price and volume of sales so as to facilitate equitable and affordable access
- ...

Global Targets for R&D

R&D related responsibilities of the Tripartite and UN Environment

<table>
<thead>
<tr>
<th>Goal</th>
<th>Objectives (outputs)</th>
<th>Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.4.1 R&amp;D coordination</td>
<td>Effective global coordination of R&amp;D activities and financing</td>
<td>Tripartite: Provide support to global coordination of R&amp;D activities (e.g. Global AMR R&amp;D Hub; STAR-IDAZ International Consortium on Animal Health)</td>
</tr>
</tbody>
</table>
Chapter 4. Access & stewardship policies

Basic principles:

- Increase access to and reduce shortages of essential and effective antibiotics by ensuring their continued availability.
- Implement international codes and standards to promote responsible and prudent use of antimicrobials in animals (terrestrial and aquatic) and plants worldwide.
- Phase out the use of antibiotics for animal growth promotion and plant protection in the absence of risk analysis.
- ...

National targets for access and stewardship

Access and Stewardship related responsibilities of the Tripartite and UN Environment

<table>
<thead>
<tr>
<th>Goal</th>
<th>Objectives (outputs)</th>
<th>Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.4.9 Dispensing and regulation</td>
<td>Strengthening of regulatory aspects for AMR</td>
<td>Tripartite: Develop guidance for countries to analyse and update their national legislation at all stages of the antimicrobial life cycle.</td>
</tr>
</tbody>
</table>
Chapter 5: Environmental aspects of AMR

Developed in close collaboration with UN Environment

Key principles

• Adopt standards, regulations and targets for improving access to and responsible and prudent use of antimicrobials and for emissions into the environment based on national context and needs;
• Apply the precautionary approach set forth in principle 15 of the Rio Declaration on Environment and Development, as well as support and facilitate the regular exchange of evidence and science-based knowledge;
• Limit the release of active pharmaceutical ingredients into the environment, including water, and ensure environmentally sound management of obsolete stocks.

Targets

Environment related responsibilities of the Tripartite and UN Environment

<table>
<thead>
<tr>
<th>Goal</th>
<th>Objectives (outputs)</th>
<th>Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.4.12 Collection and safe disposal of antibiotics from homes and farms</td>
<td>Raised awareness of the correct disposal of unused and expired antibiotics in homes and farms</td>
<td>Tripartite and UN Environment: Develop awareness and advocacy materials for the safe disposal of unused/expired antibiotics by patients and farmers (e.g. patients and farmers to bring antibiotics to pharmacies) and on take-back schemes.</td>
</tr>
</tbody>
</table>
Annex 1: Selected Financing Mechanisms

Differentiates financial needs for

- the secretariat and governing bodies
- driving change towards better stewardship, appropriate use of and access to financing R&D and access for both animal and human health

Reviews different mechanisms

Assessed contributions, replenishment, taxes, bonds, social impact/insurance/other bonds, priority review vouchers, transferable exclusivity rights, multilateral fund

Suggests mixed model:

- Secretariat: Assessed contributions
- Access & stewardship: Multilateral fund modelled after Montreal Protocol
- R&D: Social investor bond model
Annex 2: The current R&D landscape

<table>
<thead>
<tr>
<th>Initiative</th>
<th>Budget</th>
<th>Role</th>
<th>Products</th>
<th>Stages of development</th>
<th>Geographical scope</th>
<th>Appropriate use &amp; access</th>
<th>Targets specific high-priority medical needs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Multi-lateral</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CARB-X</td>
<td>USD502m (2016-21)</td>
<td>Funding and expert support</td>
<td>Therapeutics, diagnostics, preventatives, devices</td>
<td>Hit-to-lead through end of Phase 1</td>
<td>Global</td>
<td>✓</td>
<td>WHO &amp; CDC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GARDP</td>
<td>€236m (2017-23)</td>
<td>Developer</td>
<td>Therapeutics</td>
<td>Any stage of development</td>
<td>Global</td>
<td>✓</td>
<td>WHO</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>JPIAMR</td>
<td>€234m (2012-2024)</td>
<td>Public funder</td>
<td>Health products and research on resistance</td>
<td>Discovery research &amp; early stage</td>
<td>Global</td>
<td>X</td>
<td>WHO &amp; national priorities</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>European Union</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IMI: ND4BB</td>
<td>€700m (2014-18) €200-300m (2018-20)</td>
<td>Financial, in-kind and expertise</td>
<td>Therapeutics, diagnostics</td>
<td>Whole value chain</td>
<td>Global</td>
<td>✓</td>
<td>Priority pathogens including WHO priority list</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>InnovFin Infectious Diseases</td>
<td>€180m (2015-20) €80m (2018-20)</td>
<td>Loan to be paid back in case of success</td>
<td>Vaccines, drugs, medical &amp; diagnostic devices</td>
<td>Clinical development</td>
<td>EU MS and H2020 associated countries</td>
<td>X</td>
<td>Priority pathogens including WHO priority list</td>
</tr>
<tr>
<td>Industry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repair impact fund</td>
<td>USD 165m (2018-23)</td>
<td>Convertible loans and royalty-based</td>
<td>Novel therapeutics, companion diagnostics</td>
<td>Lead optimization through end of Phase 1</td>
<td>Europe &amp; U.S.</td>
<td>In progress to be established</td>
<td>WHO&amp;CDC</td>
</tr>
</tbody>
</table>
The way forward

We propose to continue working on the concept and the technical content

1) Develop the draft framework: further develop the overall concept and legal form based on the feedback

2) Member States involvement: hold additional informal consultations with Member States on specific aspects of the framework

3) Additional stakeholders: hold consultations with civil society, the private sector, NGOs, academia and professional organizations

4) Timeline and process: establish a timeline for completing a draft framework and negotiation process to reach agreement as efficiently as possible
Misuse of **ANTIBIOTICS** puts us all at risk.

Taking antibiotics when you don’t need them speeds up antibiotic resistance. Antibiotic resistant infections are more complex and harder to treat. They can affect anyone, of any age, in any country.

*Always seek the advice of a healthcare professional before taking antibiotics.*

Link to the draft framework: http://www.who.int/phi/news/WHO_OIE_FAO_UNEP_Working_paper_of_the_framework_FINAL.pdf?ua=1